logo
  

Sandoz To Begin Enrolling First Patient In MYLIGHT Study For Proposed Biosimilar Aflibercept

Sandoz, a Novartis unit, said it will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly. This marks an important milestone in the development of biosimilar aflibercept, the company noted. The MYLIGHT is a randomized, double-blind, parallel 2-arm study, which is projected to include 460 patients across 20 countries.

Aflibercept binds and inhibits ocular VEGF-A, and prevents abnormal growth of blood vessels in the choroid which impact visual function. It improves visual acuity in patients with neovascular retinal diseases.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple is set to open the Apple Tower Theatre in Los Angeles on Thursday. Apple has converted the 94-year old historic downtown LA art deco theatre into a show-stopping retail store or creative hub for the 21st century. This will be the first Apple Store in downtown LA and the 26th location in greater LA. Bea Lydecker's Naturals, Inc. is recalling six Living Free brand dietary supplement products citing undeclared soy lecithin, the U.S. Food and Drug Administration said. According to the agency, the labels declare lecithin but do not declare soy lecithin. Investment banking major Morgan Stanley plans to block employees and clients who are not fully vaccinated against COVID-19 from entering its New York offices, the Financial Times reported citing an internal memo. The policy is expected to come into effect on July 12, and all unvaccinated employees will lose building access from then onwards.
Follow RTT